Allogene, SpringWorks Collaborate to Test ALLO-715, Nirogacestat Combo for RRMM
Allogene Therapeutics and SpringWorks Therapeutics have launched a clinical trial collaboration to conduct a Phase…
Myeloma
Sanofi Partners to Develop Diagnostic Test for Multiple Myeloma Patients on Potential Therapy
Sanofi announced that it partnered with Sebia to develop a new multiple myeloma diagnostic test that will help to mitigate the interference of isatuximab…
FDA Grants Priority Review to Belantamab Mafodotin for Heavily-treated Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted priority review status to GlaxoSmithKline‘s application seeking the approval of belantamab mafodotin for the treatment of heavily…
Darzalex Combo Approved in Europe to Treat Transplant-eligible Myeloma Patients
The European Commission has approved Darzalex (daratumumab), in combination with standard pre-transplant therapy, to treat newly diagnosed multiple myeloma patients who are…
NexImmune to Initiate Phase 1/2 Trial of NEXI-002 Cell Therapy for RRMM Patients
NexImmune will soon initiate a Phase 1/2 trial evaluating its cell therapy NEXI-002 in people with multiple myeloma who failed three or…
IMF, Medscape Oncology Offer Medical Education Series on Continuous Treatment in Myeloma
In partnership with Medscape Oncology, the International Myeloma Foundation (IMF) is offering a professional education series on continuous treatment in multiple…
First Mainland China Patient Dosed in Pivotal Phase 2 Trial Testing MOR202 in Multiple Myeloma
I-Mab Biopharma has dosed the first patient in mainland China in its ongoing, pivotal Phase 2 trial assessing MorphoSys‘s investigational antibody therapy…
Pivotal DREAMM-2 Trial Supports Belantamab Mafodotin’s Use for Heavily-treated Multiple Myeloma
Treatment with belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, resulted in clinically meaningful responses in about one-third of hard-to-treat multiple…
Myeloma Patients in Phase 1 Trial Show High Response Rates with REGN5458 Treatment
Treatment with Regeneron Pharmaceuticals‘ investigational therapy REGN5458 was well tolerated and significantly lowered the tumor burden in more than…
PNK-007 Treatment After Stem Cell Transplant Leads to Good Response Rates in Multiple Myeloma Patients, Early Trial Data Show
A single infusion of Celularity‘s PNK-007 — an investigational cell therapy derived from placental stem cells — is safe and leads to good response…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML